Summary Regulus is a retail heavy stock which has recently tripled on mere Phase I results. Regulus’ drug is not a one shot cure for Hep C and is inferior to Gilead’s Harvoni. As the stock has spiked, insiders and partners have been very quick to dump large amounts of stock. This article is the…

Read More